Italian contrast firm Bracco said that results from the Patients with Renal Impairment and Diabetes undergoing CT (PREDICT) trial show no statistically significant difference between its Isovue-370 low-osmolar CT contrast agent and the Visipaque 320 isomolar agent (GE Healthcare, Chalfont St. Giles, U.K.) in the rate of contrast-induced nephropathy in high-risk patients undergoing CT studies.
The results were recently published in the American Journal of Roentgenology, according to Bracco of Milan.
Related Reading
Bracco completes E-Z-EM acquisition, April 2, 2008
Bracco to acquire E-Z-EM, October 30, 2007
Bracco, ImaRx sign licensing pact, July 4, 2007
Copyright © 2008 AuntMinnie.com
